Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Delaware court denies SIGA reargument in PharmAthene smallpox case

This article was originally published in Scrip

Executive Summary

Shares SIGA Technologies sunk as low as 8.6%, or 19 cents, on 19 December on word that the firm's motion for reargument was denied by a Delaware Chancery Court in a case in which the company was ordered in September to evenly split any profits it gains from the sale of its investigational smallpox antiviral drug ST-246 with PharmAthene (scripintelligence, 26 September 2011).



Related Companies